Date and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor Forum

First Wave BioPharma, a leading clinical-stage biopharmaceutical company, is set to make waves at the highly anticipated 2023 BIO Investor Forum. The event, taking place on October 17th at the Hilton San Francisco, will feature a captivating presentation by First Wave BioPharma’s Chairman, President, and CEO, James Sapirstein.

Attendees can look forward to gaining valuable insights into the company’s groundbreaking work in the field of gastrointestinal (GI) diseases. With a focus on developing targeted, non-systemic therapies, First Wave BioPharma is revolutionizing the treatment landscape for patients suffering from these conditions.

During the presentation, Sapirstein and the First Wave BioPharma management team will highlight the company’s robust business and clinical development strategy. They will also showcase recent corporate achievements and discuss anticipated milestones that are set to shape the future of GI disease treatment.

First Wave BioPharma’s therapeutic development pipeline boasts multiple Phase 2 clinical stage programs, each built around three proprietary technologies. One of these technologies is the biologic adrulipase, a recombinant lipase enzyme designed to aid in the digestion of fats and nutrients for patients with exocrine pancreatic insufficiency caused by cystic fibrosis and chronic pancreatitis.

Another promising technology in their pipeline is capeserod, a selective 5-HT4 receptor partial agonist. First Wave BioPharma plans to pursue capeserod for various gastrointestinal indications, further expanding their potential impact on patients’ lives.

Additionally, First Wave BioPharma is advancing niclosamide, an oral small molecule with anti-inflammatory properties. This innovative treatment shows great promise for patients suffering from inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.

Headquartered in Boca Raton, Florida, First Wave BioPharma is at the forefront of cutting-edge research and development in the biopharmaceutical industry. Their commitment to improving the lives of those affected by GI diseases is evident in their groundbreaking technologies and clinical advancements.

Investors attending the BIO Investor Forum will have the opportunity to engage in one-on-one meetings with the First Wave BioPharma management team. These meetings will provide a deeper understanding of the company’s vision, strategy, and potential for growth.

First Wave BioPharma’s participation in this prestigious event underscores their dedication to advancing the field of GI disease treatment. With their innovative therapies and unwavering commitment to patient well-being, First Wave BioPharma is poised to make a lasting impact on the lives of countless individuals.

For more information about First Wave BioPharma and their groundbreaking work, please visit their website at www.firstwavebio.com.